Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 279

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 279
---
962 |     |           |      – |
| Lease liability                          |     |       |  53,142 |     |        |  36,726 |     |           | 16,416 |
|                                          |     | $     | 628,160 |     | $      | 611,744 |     | $         | 16,416 |

| October                                  
 31, 2023                                 |     | Total |         |     | Within 
 1 year |         |     | Within    
 2-5 years |   |
|:-----------------------------------------|:----|:------|--------:|:----|:-------|--------:|:----|:----------|:--|
| Accounts payable and accrued liabilities |     | $     | 617,004 |     | $      | 617,004 |     | $         | – |
| Due to related parties                   |     |       |  42,433 |     |        |  42,433 |     |           | – |
|                                          |     | $     | 659,437 |     | $      | 659,437 |     | $         | – |

F-33 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 13. | Capital    
 Management |

The Company manages its capital to maintain its ability to continue as a going concern and to provide returns to shareholders and benefits to other stakeholders. The capital structure of the Company consists of cash and equity comprised of issued share capital and share premium, warrants and share-based payment reserve.

The Company manages its capital structure and makes adjustments to it in light of economic conditions. The Company, upon approval from its Board, will balance its overall capital structure through new share issuances or by undertaking other activities as deemed appropriate under the specific circumstances.

The Company is not subject to externally imposed capital requirements and the Company’s overall strategy with respect to capital risk management remains unchanged from the year ended October 31, 2024.

| 14. | Commitments |

| b. | On March 19, 2024, the Company entered into a License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, which provides to the Company with an exclusive, perpetual, worldwide and sublicensable license to use to Yissum’s patent titled “psychedelic compounds, methods of their preparation and uses thereof”  to further develop, manufacture, and commercial